Effect of study partner on the conduct of Alzheimer disease clinical trials

Neurology

Volumn 80, Issue 3, 2013, Pages 282-288

  Grill, Joshua D ^a   Raman, Rema ^b   Ernstrom, Karin ^b   Aisen, Paul ^b   Karlawish, Jason ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; CLINICAL DEMENTIA RATING; CLINICAL RESEARCH; DAILY LIFE ACTIVITY; HUMAN; METHODOLOGY; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PATIENT PARTICIPATION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPOUSE;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAREGIVERS; CLINICAL TRIALS AS TOPIC; DEMOGRAPHY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MODELS, STATISTICAL; NEUROPSYCHOLOGICAL TESTS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84873670904     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31827debfe     Document Type: Article

References (25)

1. Grill JD, Karlawish J. Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. Alzheimers Res Ther 2010;2:34.
2. Thies W, Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimers Dement 2011;7:208-244.
3. Edland SD, Emond JA, Aisen PS, Petersen RC. NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia. Alzheimer Dis Assoc Disord 2010;24:159-164.
4. Norton MC, Piercy KW, Rabins PV, et al. Caregiver-recipient closeness and symptom progression in Alzheimer disease. The Cache County Dementia Progression Study. J Gerontol B Psychol Sci Soc Sci 2009;64:560-568.
5. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003; 289:2819-2826. (Pubitemid 37430117)
6. Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 2008;300: 1774-1783.
7. Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical pro gression of Alzheimer disease. Arch Gen Psychiatry 2011; 68:853-861.
8. Quinn JF, Raman R, Thomas RG, et al. Docosahexae-noic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010;304: 1903-1911.
9. Sano M, Bell KL, Galasko D, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alz heimer disease. Neurology 2011;77:556-563.
10. Rafii MS, Walsh S, Little JT, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 2011;76:1389-1394.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
12. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
13. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414. (Pubitemid 23346995)
14. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S33-S39.
15. Alzheimer's Association. 2008 Alzheimer's disease facts and figures. Alzheimers Dement 2008;4:110-133.
16. Alzheimer's Association. Alzheimer's Association and National Alliance for Caregiving. Families care: Alzheimer's disease caregiving in the United States, 2004. Available at: http://www.alz.org/national/documents/report- familiescare. pdf. Accessed May 5, 2012.
17. Conde-Sala JL, Garre-Olmo J, Turro-Garriga O, Vilalta-Franch J, Lopez-Pousa S. Differential features of burden between spouse and adult-child caregivers of patients with Alzheimer's disease: an exploratory comparative design. Int J Nurs Stud 2010;47:1262-1273.
18. Conde-Sala JL, Garre-Olmo J, Turro-Garriga O, Lopez-Pousa S, Vilalta-Franch J. Factors related to perceived quality of life in patients with Alzheimer's disease: the patient's perception compared with that of caregivers. Int J Geriatr Psychiatry 2009;24:585-594.
19. Conde-Sala JL, Garre-Olmo J, Turro-Garriga O, Vilalta-Franch J, Lopez-Pousa S. Quality of life of patients with Alzheimer's disease: differential perceptions between spouse and adult child caregivers. Dement Geriatr Cogn Disord 2010;29:97-108.
20. Grill JD, Monsell S, Karlawish J. Are patients whose study partners are spouses more likely to be eligible for Alzheimer's disease clinical trials? Dement Geriatr Cogn Dis-ord 2012;33:334-340.
21. Faison WE, Schultz SK, Aerssens J, et al. Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future. Int Psychogeriatr 2007;19:539-558. (Pubitemid 46707427)
22. Janevic MR, Connell CM. Racial, ethnic, and cultural differences in the dementia caregiving experience: recent findings. Gerontologist 2001;41:334-347. (Pubitemid 32525550)
23. Alzheimer's Association. 2010 Alzheimer's disease facts and figures. Alzheimers Dement 2010;6:158-194.
24. Bernick C, Cummings J, Raman R, Sun X, Aisen P. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol 2012;69:901-905.
25. Albert SM, Sano M, Marder K, et al. Participation in clinical trials and long-term outcomes in Alzheimer's disease. Neurology 1997;49:38-43. (Pubitemid 27328679)